Nanomagnetic Biomaterial Measurement Business Through a Joint Venture with Ferrotec
First written in FY2023-Q1. 2 of 4 entries say "Achieved", first in FY2023-Q2. Latest entry: FY2025.
0 other companies' latest entry also says "Achieved".
- FY2025AchievedAnnual report
「PF・BioLine, an equity-method jointly controlled entity, was excluded from equity-method affiliates after the resolution to dissolve it and completion of its liquidation as of 31 March 2025.」
The joint venture PF・BioLine with Ferrotec progressed from the post-establishment operating stage to dissolution and completion of liquidation. - FY2023RestatedAnnual report
「PF・BioLine is a jointly controlled entity accounted for under the equity method that conducts research and development and sales of products for measuring biological substances.」
The business activities of PF・BioLine, the joint venture with Ferrotec, were disclosed for the full fiscal year as an equity-method jointly controlled entity, moving beyond the planning stage. - FY2023-Q2AchievedAnnual report
「Business combination date 12 December 2022" Establishment of a joint venture in which the ownership ratio of the Company to Ferrotec Holdings Corporation is 51:49 "Name of the combined company PF・BioLine」
The joint venture PF・BioLine with Ferrotec Holdings Corporation was established on 12 December 2022, with an ownership ratio of 51% for the Company and 49% for Ferrotec. The business of researching and developing and selling products for measuring biological substances using nanomagnetic particles progressed from the planning stage to implementation through the establishment of the joint venture. - FY2023-Q1First statedAnnual report
「At a meeting of the Board of Directors held on 24 October 2022, the Company resolved to establish a joint venture with Ferrotec Holdings Corporation. The joint venture will conduct research and development and sell products for measuring biological substances using nanomagnetic particles by combining Ferrotec's manufacturing technologies for magnetic fluids and Peltier devices and related products with the Company's technologies for automated processing systems for magnetic-particle reaction control, PCR testing and immunoreaction testing, and related products.」
The resolution provided for the establishment of PF・BioLine, a joint venture with Ferrotec Holdings Corporation, to combine Ferrotec's magnetic fluid and Peltier device technologies with PSS's technologies for magnetic-particle reaction control and automated PCR and immunoreaction testing. The joint venture was scheduled to be established in early December 2022, with capital of ¥50 million and an ownership ratio of 49% for Ferrotec and 51% for the Company. The venture was intended to support definitive diagnoses of infectious diseases, cancer and Alzheimer's disease, among others, and was positioned as a theme of the medium-term business plan to launch new products based on the Company's own technologies.